Merit Medical Systems delivered a quarter with two different headlines. On the Earnings Whispers normalized basis, the company earned $1.01 per share. That missed the $1.04 consensus and fell 9.0% short of the $1.11 Earnings Whisper number, though earnings still grew 13.5% year over year. Revenue was cleaner: $416.24 million beat the $410.39 million consensus by 1.4% and rose 8.4%. Management told a more triumphant story, reporting non-GAAP EPS of $1.12, up 22% and above its own $0.98 to $1.08 guide, and raising full-year EPS guidance for the third straight time. That is the central tension. The operating business is executing well above plan, but investors with whisper-level expectations were looking for a cleaner beat than the normalized figure delivered.

The gap between the two EPS figures deserves scrutiny. It is almost exactly the $0.11 per share of performance-based share compensation that Merit adds back in its non-GAAP reconciliation. That expense is a real and recurring cost of running the business. On a GAAP basis the picture is still strong: EPS rose 51% to $0.70, and GAAP operating margin widened to 14.1% from 11.1%. Non-GAAP operating margin of 21.3% expanded 160 basis points and landed at the top of guidance. The weaker spot is gross margin. Non-GAAP gross margin fell to 52.8% from 53.6%, a decline of about 81 basis points, after expanding roughly 98 basis points in the second quarter. Management cited platinum-related manufacturing variances, a bonus true-up and freight. Operating leverage, not product economics, carried the margin story this quarter.

The top line is where the quarter was most convincing. Organic constant-currency growth of roughly 9% matched the second quarter's pace and was far above the first quarter's 3.7% ex-divestiture rate. That makes this a sustained re-acceleration rather than a one-quarter blip.

• **U.S.:** revenue grew 11%.
• **Therapeutic:** organic growth of 11%, with endoscopy up 33% and oncology up 16% on pent-up ScoutMD demand.
• **OEM:** grew about 15% after a flat first half that included a 14% decline in the first quarter.

Not everything is pulling its weight. Procedural Solutions fell 16% and Renal Therapies slipped 2%. International grew only 3%, or 6% excluding China. Management trimmed its second-half China outlook by about $4 million, citing volume-based procurement and buy-local pressure.

Guidance moved in the right direction, but the raise was more about flow-through than a new forecast. Full-year non-GAAP EPS guidance rose to $4.33 to $4.37 from $4.25 to $4.35, a path that began at $4.01 to $4.15. Other updates:

• Organic constant-currency growth guidance moved to 7.1% to 7.6%.
• Full-year operating margin is now expected at 21.2% to 21.4%, versus 20.6% to 21.0% initially.
• Management expects cumulative free cash flow under its Continued Growth Initiative near $600 million, well ahead of the more-than-$400 million target.

The revenue range was raised mainly at the low end, so the implied fourth quarter decelerates to 7% to 8% organic against tougher comparisons. Bears have legitimate ammunition elsewhere too. Inventory is up roughly $60 million year to date, and year-to-date free cash flow of $129.5 million trails last year's $141.6 million. The Viewpoint/OneMark integration is running slower than hoped, Rhapsody faces stiff competition, and Section 232 tariff uncertainty lingers.

Forward catalysts are building. Management announced:

• The SoloPace acquisition, which brings Merit into TAVR temporary pacing. It is immaterial to 2026 and expected to be slightly accretive in 2027.
• A new Chief Operations Officer focused on working capital and operational execution.
• A February 11, 2027 investor day to unveil 2027 to 2029 targets.

Management also said a validated platinum alternative is ramping to address the gross-margin variance. That is the one fix the quarter most clearly needed.

The market had already priced in plenty of good news. Shares entered the report at $92.21, up 5.2% from the open after the July report and nearly 20% above the 200-day moving average. They sat just 2.8% below a 52-week high of $94.85 set three days earlier, near the top of an inter-earnings range that began at $82.77. Investor sentiment, by contrast, stayed slightly negative and was essentially unchanged, moving from -0.13 to -0.12. Earnings Whispers trend signals were uniformly positive heading in. With price this extended, a normalized miss against a $1.11 whisper matters more than it would have from a lower base.

The bottom line is that Merit's operating story improved again: organic growth held at 9%, operating margins expanded, and guidance rose for a third time. The quality of the earnings beat is less impressive than management's non-GAAP framing suggests, and gross margin moved the wrong way. With the stock near its highs and the fourth-quarter outlook implying deceleration, the platinum fix and the February investor day now carry much of the burden of extending the rally.